Shots:

• The P-III study evaluates Byooviz (0.5 mg- IVT) vs ranibizumab in 634 patients with nAMD. The results will be presented at EURETINA 2021
• The 1EPs are changed from baseline in BCVA @8wks. and change in CST @4wks. with both EPs- followed by 52wks. The post-hoc analysis showed that the baseline age- BCVA- CST- and total lesion size were identified to be associated with the visual acuity & anatomical outcomes
• In subgroup analysis- similar visual outcomes of 2 products in change from baseline in BCVA in multiple subgroups were observed & support an equivalent clinical efficacy. Byooviz is an effective & valuable treatment option for nAMD patients globally

| Ref: Samsung Bioepis | Image: Samsung Bioepis